Ahn-Gook Pharmaceutical Co. Ltd Total Assets
Ahn-Gook Pharmaceutical Co. Ltd total assets. Based on the latest financial reports, Ahn-Gook Pharmaceutical Co. Ltd (001540) holds total assets worth ₩303.42 Billion KRW (≈ $205.63 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Ahn-Gook Pharmaceutical Co. Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Ahn-Gook Pharmaceutical Co. Ltd (2011–2024)
Total assets of Ahn-Gook Pharmaceutical Co. Ltd from 2011 to 2024. This chart illustrates how Ahn-Gook Pharmaceutical Co. Ltd's total assets have evolved over time, based on quarterly financial data. See 001540 stock price for real-time trading data and today's change.
Ahn-Gook Pharmaceutical Co. Ltd - Asset Composition Analysis
Ahn-Gook Pharmaceutical Co. Ltd Total Assets Breakdown (December 2024)
Ahn-Gook Pharmaceutical Co. Ltd total assets breakdown as of December 2024. Ahn-Gook Pharmaceutical Co. Ltd's total assets of ₩303.42 Billion consist of 44.6% current assets and 55.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩9.78 Billion | 2.0% |
| Accounts Receivable | ₩58.72 Billion | 19.4% |
| Inventory | ₩44.67 Billion | 14.8% |
| Property, Plant & Equipment | ₩120.07 Billion | 39.7% |
| Intangible Assets | ₩3.90 Billion | 1.3% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Ahn-Gook Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Ahn-Gook Pharmaceutical Co. Ltd's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ahn-Gook Pharmaceutical Co. Ltd's current assets represent 44.6% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 2.0% of total assets in 2024, down from 3.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 2.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 39.7% of total assets.
Ahn-Gook Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of Ahn-Gook Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Ahn-Gook Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.79 | 1.74 | 2.49 |
| Quick Ratio | 1.18 | 1.19 | 1.99 |
| Cash Ratio | 0.00 | 0.17 | 0.00 |
| Working Capital | ₩59.36 Billion | ₩57.65 Billion | ₩66.75 Billion |
Ahn-Gook Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Ahn-Gook Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.54 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 26.8% |
| Total Assets | ₩302.54 Billion |
| Market Capitalization | $73.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ahn-Gook Pharmaceutical Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Ahn-Gook Pharmaceutical Co. Ltd's assets grew by 26.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ahn-Gook Pharmaceutical Co. Ltd (2011–2024)
The table below shows the annual total assets of Ahn-Gook Pharmaceutical Co. Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩302.54 Billion ≈ $205.02 Million |
+26.80% |
| 2023-12-31 | ₩238.60 Billion ≈ $161.69 Million |
+6.56% |
| 2022-12-31 | ₩223.91 Billion ≈ $151.74 Million |
+5.72% |
| 2021-12-31 | ₩211.80 Billion ≈ $143.53 Million |
+5.00% |
| 2020-12-31 | ₩201.70 Billion ≈ $136.69 Million |
-7.46% |
| 2019-12-31 | ₩217.96 Billion ≈ $147.71 Million |
+2.36% |
| 2018-12-31 | ₩212.92 Billion ≈ $144.30 Million |
+2.34% |
| 2017-12-31 | ₩208.07 Billion ≈ $141.00 Million |
+6.01% |
| 2016-12-31 | ₩196.27 Billion ≈ $133.01 Million |
-0.80% |
| 2015-12-31 | ₩197.85 Billion ≈ $134.08 Million |
+10.49% |
| 2014-12-31 | ₩179.07 Billion ≈ $121.35 Million |
+9.70% |
| 2013-12-31 | ₩163.24 Billion ≈ $110.63 Million |
-2.74% |
| 2012-12-31 | ₩167.83 Billion ≈ $113.74 Million |
+2.43% |
| 2011-12-31 | ₩163.85 Billion ≈ $111.04 Million |
-- |
About Ahn-Gook Pharmaceutical Co. Ltd
Ahn-Gook Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products. The company's pharmaceutical products include Cinatura and Revo Tension. The company was founded in 1959 and is headquartered in Seoul, South Korea.